

PRIME ENGLISH NEWS AND INFORMATION AROUND THE VIENNA STOCK EXCHANGE

21/24

21st Austria ATX-Prime Stocks Week 21 ATX TR 3747.03 -0.09% % week

1995 -0.25% 49.44%

Aluflexpack Agrana

Addiko Bank

13.50 -0.74% -4.26% **Amag**

26.70 AT&S

Price

-1.95% -15.74%

9.09%

% vtd

22.16 Bawag

28.28% 61.55 2.33%

stock3

17.50 -2.23% -3.31% **CA Immo**

0.82%

-8.84%

29.58

DO&CO 147.40 0.00% 9.67%

Erste Group

47.13 28.31% -0.82%

FACC

6.97 -1.41% 19.55%

Flughafen Wien

49.20 0.41% -3.34%

Frequentis

1.84% 27.70 1.47%

Immofinanz

23.90 13.54%

Kapsch TrafficCom

8.94 -0.22% 2.76%

Montana Aerospace Marinomed Biotech

14.65 -11.21% -49.83%

Palfinger

24.05 0.63% -4.56%

Pierer Mobility

38.20 -3.29% -23.14%

Porr

Dear active investors.

ATX TR closed week 21 slightly lower, but finished the first 100 Trading days in 2024 better than Germanys DAX. Best Stock in Week 21 was S Immo, Immofinanz starts preparations for a squeeze-out of S Immo. Further news came from Valneva, Verbund, CA Immo, Marinomed, Porr and Uniqa.

BSNgine weekly Spitout: The ATX TR down -0,09% to 8.502,2 points this week. Year-to-date the ATX TR is now at 11,64%. Up to now there were 60 days with a positive and 41 with a negative gain. From the year-high we are 0,75% away, from the low 15,26%. Statistically the best weekday so far 2024 is Thursday with 0,16%, the weakest is Wednesday with -0,03%.

These are the best-performers this week: S Immo 11,48% in front of Kapsch TrafficCom 2,76% and Telekom Austria 2,48%. And the following stocks performed worst: SBO -12,85% in front of Marinomed Biotech -11,21% and Warimpex -6,34%.

Further highlights this week: **Bawag** for 4 days in a row up (2,33% gain from 60,15 to 61,55), also **Erste Group** 4 days down (0,92% loss from 47,57 to 47,13), Marinomed Biotech 3 days down (10,67% loss from 16,4 to 14,65), Lenzing 3 days down (4,46% loss from 35,85 to 34,25), **SBO** 3 days down (14,73% loss from 46,15 to 39,35).

Best-performers year-to-date as of now: S Immo 63,2% (last year: 0,16 percent) followed by Addiko Bank 49,44% (last year: 5,53 percent) and Erste Group 28,31% (last year: 22,84 percent). And the worst-performing stocks year-to-date: Marinomed Biotech -49,83% (Vorjahr: -48,23 percent), followed by Pierer Mobility -23,14% (Vorjahr: -26,59 percent) and Semperit -18,64% (Vorjahr: -28,56 percent).

High above the MA200: **SImmo** 43,04%, **Addiko Bank** 36,77% and **Erste Group** 25.49%.

Down under the MA200: Marinomed Biotech -52,02%, Pierer Mobility -29,79% and **Semperit** -22,02%.

MONDAY

20

Valneva: Valneva, a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer (CSO) and Executive Committee member, effective June 3, 2024. Dr. Schuitemaker brings more than two decades of experience in vaccine discovery and development. She formerly

served as Global Head of Viral Vaccine Discovery and Translational Medicine at Johnson & Johnson (J&J), with responsibility for the strategy and execution of vaccine programs on COVID-19, HIV, RSV, Ebola, and multiple other viral disea-







21STAUSTRIA WEEKLY



14.34	-1.10%	12.91%
Österreichiscl	he Post	
31.00	-2.82%	-5.20%
Polytec Group)	
3.59	-1.37%	2.43%
RBI		
17.21	-2.16%	-7.82%
RWT AG		
3.48	-2.79%	-13.00%
Semperit		
11.52	-3.03%	-18.64%
S Immo		
20.40	11.48%	63.20%
Sportradar Gr	oup	
9.50	-3.06%	-4.19%
Ctrobog		
Strabag 41.00	-0.49%	-0.97%
		0.5770
Telekom Aust		17 / 60/
8.68	2.48%	13.46%
UBM		
20.10	2.29%	-4.74%
Uniqa		
8.25	-0.36%	10.59%
Varta AG		
10.99	-8.34%	-47.04%
VAS AG		
9.00	1.12%	1.12%
Verbund		
74.00	2.28%	-11.96%
VIG		
31.45	0.80%	18.68%
Valneva		
3.88	-5 37%	-17.80%
		17.00%
Wienerberge		16.000/
35.32	-0.23%	16.88%
Warimpex		
0.77	-6.34%	3.09%
Zumtobel		
6.06	1.00%	-3.50%

se targets for almost 14 years.

Valneva: weekly performance: -5.37%

TUESDAY

21

Verbund: Verbund, Austria's leading utility company, has taken another step in its long-standing green finance strategy and successfully issued a green bond including biodiversity. The green bond including biodiversity for EUR 500 million with a term of 7 years was extremely well received by the investor community in a

competitive environment and was therefore oversubscribed more than 6 times at the peak. The high demand made it possible to set the interest rate at an attractive level of 3.250%. The company intends to use up to 90% of the proceeds from the bond to finance the construction of the 380 kV Salzburg high-voltage line (Salzburg line). In addition, Verbund intends to finance the projects "LIFE Riverscape Lower Inn" and "LIFE Project Blue Belt Danube Inn" (the "Biodiversity Projects"). The biodiversity projects are part of the Verbund program to improve ecology and biodiversity around hydropower plants in Austria and Bavaria (Germany).

Verbund: weekly performance: 2.28%

CA Immo: CA Immo, the real estate company specializing in high-quality office space, can report a stable operating development for Q1 2024. CA Immo recorded a 4% increase in rental income to €64.0m despite the sale of non-strategic properties. This development is primarily due to higher rental income in the portfolio and the completion of project developments in previous years, which more than compensated for the decline in rental income from the sale of non-strategic properties as part of the strategic capital rotation program. The result from property sales amounted to €–0.3m after €22.3m as at 31.3.2023. Earnings before interest, taxes, depreciation and amortization (EBITDA) stood at €37.0m, 35% below the previous year 's figure of €56.5m, mainly due to the lower sales result.

CA Immo: weekly performance: 0.82%



Marinomed: Marinomed Biotech AG (VSE:MARI) announces revenues of EUR 0.7 million recorded in the first quarter of 2024. After observing record revenues from Carragelose product sales heavily influenced by the SARS-CoV-2 pandemic over the past years, the revenue in the first quarter of 2024 has declined to levels observed

before the pandemic. This decline is mostly due to high inventories and the return of seasonality, causing a drop in customer demand. Due to cost-conscious cash management, cash and cash equivalents stood at EUR 1.9 million compared to EUR 2.6 million at the end of 2023. The operating result (EBIT) stood at EUR -1.9 million (Q1 2023: EUR -1.4 million) and the loss for the period amounted to EUR -2.1 million (Q1 2023: EUR -2.1 million). "Although we are making constant progress and are working on several initiatives in parallel, the situation remains challenging. Revenues generated by the sales of Carragelose products will likely be characterized by the post-pandemic overhang of customers' inventories and lower demand until the end of the year. Reaching an agreement with the EIB and real estate lenders to suspend repayments by 18 months has given us some more time and flexibility. At the same time, we have taken se-







21STAUSTRIA WEEKLY



veral measures to reduce the cash burn as much as possible", Pascal Schmidt, CFO of Marinomed, adds. "However, closing deals with corresponding upfront and milestone payments for our Marinosolv assets remains our priority. At the same time, we are aiming for a decision regarding the evaluation of the whole Carragelose portfolio by the end of the first half of the year. We are optimistic that the cash flows generated from our efforts will be sufficient to cover our financing needs."

Marinomed Biotech: weekly performance: -11.21%

THURSDAY

23

Porr: Construction group Porr proved exceptionally stable in the first quarter of 2024. PORR's production output totalled EUR 1,323m in the first quarter of 2024, making it 4.1% higher than the previous year's figure. In the first quarter – traditionally the weakest quarter of the year due to seasonal factors – PORR's revenue re-

mained stable compared to the same period last year at EUR 1,275.6m (1-3/2023: EUR 1,266.3m). Thanks to efficient supplier management, the cost of materials and other related production services was reduced by 4.0%. This resulted in a substantial increase in EBIT of 14.4% to EUR 11.3m. In addition, PORR saw EBT almost double from EUR 4.5m to EUR 8.0m. PORR CEO Karl-Heinz Strauss sees grounds for optimism: "We expect the industry to recover over the course of the year, partly due to the expected interest rate cuts and the ongoing support measures from the European Recovery and Resilience Facility".

Porr: weekly performance: -1.10%

FRIDAY

24

Uniqa: The premiums written of UNIQA Insurance Group AG including savings portions from unit-linked and index-linked life insurance rose by 10.9 per cent to €2,184.3 million in the first three months of 2024 compared with the same period of the previous year (1 – 3/2023: €1,969.4 million). Above all, property and casualty

insurance and health insurance contributed to this very pleasing growth. The UNIQA Group's earnings before taxes improved significantly by 16.8 per cent to €145.1 million (1-3/2023: €124.3 million). Consolidated profit/(loss) – the proportion of net profit/(loss) for the period attributable to the shareholders of UNIQA Insurance Group AG – increased by 5.9 per cent to €106.9 million (1-3/2023: €101.0 million). The solvency capital requirement ratio in accordance with Solvency II, which is considered to be a measure of capitalisation, was at a high level at UNIQA at around 264 per cent as at the reporting date of 31 March 2024.

Uniqa: weekly performance: -0.36%

Immofinanz/S Immo: Immofinanz starts preparations for a squeeze-out of S Immo AG. In the course of the squeeze-out, shares in S Immo held by minority shareholders shall be transferred to Immofinanz as main shareholder in exchange for appropriate cash compensation. Together with its parent company CPI Property Group S.A. Immofinanz holds a stake of approximately 88.37% in the share capital of S Immo, taking into account the treasury shares of S Immo of approximately 92.54%.. The squeeze-out currently relates to 5,246,664 S Immo shares, which corresponds to approximately 7.13% of the share capital.









21STAUSTRIA WEEKLY



with
love
from
Vienna

Immofinanz: weekly performance: 0.21%' S Immo: weekly performance: 11.48%

THE NEXT 21st AUSTRIA WEEKLY WILL BE
ISSUED NEXT SATURDAY
HEAR OUR ENGLISH SPOKEN STOCK MARKET
PODCAST WITH ALLISON AND CHRIS EVERY
SUNDAY ON CHRISTIAN-DRASTIL.COM/
PODCAST









Publisher: FC Chladek Drastil GmbH, Czerninpl. 4, 1020 Wien · complete imprint: boerse-social.com/impressum ·

Petzwinkler · bsngine: Josef Chladek, Christian Drastil

subscription: boerse-social.com/21st